Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The main purpose of this study is to see how cells taken from the lining of the intestine behave in the laboratory with exposure to gluten and other substances that act on the immune system. The cells lining the intestine of a person with celiac disease should be different than a person without celiac disease. The study doctors would like to see how the cells react after coming in contact with gluten and if substances that act on the immune system can prevent gluten related inflammation. Examples of these substances include steroids. The cells should produce chemicals of their own in response to the gluten. These other chemicals will be measured and the results compared between those with:
The primary purpose of this study is to determine the effect of in-vitro introduction of gluten on inflammatory response primarily Interferon-γ and other cytokines, such as IL-15, IL-18 and IL-21, in cultures obtained from small intestinal mucosal biopsy samples of subjects who underwent upper endoscopy.
Secondary goals include comparing the inflammatory response to immunosuppressants and cytokines after exposing the cultures obtained from small intestinal mucosal biopsies taken from RCD I subjects with intestinal mucosal biopsies taken from subjects with CeD controlled on a Gluten-Free Diet (GFD), uncontrolled CeD, Gluten sensitivity and Non-celiac Controls.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| refractory celiac disease | |||
| well-controlled celiac disease | |||
| uncontrolled celiac disease | either newly diagnosed with celiac disease or not on a gluten-free diet | ||
| gluten-sensitivity | |||
| disorders other than celiac disease. |
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| change in interferon gamma | in vitro culture stimulated with gluten | 0, 6, and 24 hours |
| Measure | Description | Time Frame |
|---|---|---|
| change in interleukin-15 | in vitro culture stimulated with gluten | 0, 6, and 24 hours |
| change in interleukin-18 | in vitro culture stimulated with gluten |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Subjects will be selected from patients undergoing a clinically indicated upper endoscopy at Beth Israel Deaconess Medical Center
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Daniel A Leffler, MD, MS | Beth Israel Deaconess Medical Center | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Beth Israel Deaconess Medical Center | Boston | Massachusetts | 02215 | United States |
Not provided
| ID | Term |
|---|---|
| D002446 | Celiac Disease |
| ID | Term |
|---|---|
| D008286 | Malabsorption Syndromes |
| D007410 | Intestinal Diseases |
| D005767 | Gastrointestinal Diseases |
| D004066 | Digestive System Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
Duodenal biopsy samples
| 0, 6, and 24 hours |
| change in interleukin-21 | in vitro culture stimulated with gluten | 0, 6, and 24 hours |
| D008659 | Metabolic Diseases |
| D009750 | Nutritional and Metabolic Diseases |